• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SALIX PHARMACEUTICALS, INC. DEFLUX INJECTABLE GEL; AGENT,BULKING,INJECTABLE FOR GASTRO-UROLOGY USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SALIX PHARMACEUTICALS, INC. DEFLUX INJECTABLE GEL; AGENT,BULKING,INJECTABLE FOR GASTRO-UROLOGY USE Back to Search Results
Model Number DEFLUX
Device Problems Improper or Incorrect Procedure or Method (2017); Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Renal Failure (2041); Obstruction/Occlusion (2422)
Event Type  Injury  
Manufacturer Narrative
Investigation of this event is in progress.A follow-up report will be submitted upon completion of the investigation.
 
Event Description
Literature article "delayed obstruction with asymptomatic loss of renal function after dextranomer/hyaluronic acid copolymer (deflux) injection for vesicoureteral reflux: a close look at a disturbing outcome" by dimitri papagiannopoulos, ilina rosoklija, earl cheng, elizabeth yerkes, reports: "three cases where deflux was used in off-label fashion, resulting in delayed ureteral obstruction and loss of renal function (range 18-52 months post-operatively).We now place increased emphasis on the need for long-term follow-up after deflux in both routine and complex cases, particularly in situations of off-label use." case three of three: a (b)(6) patient with recurrent bladder and bowel dysfunction (bbd) was treated with double hit deflux injection.During intraoperative observations the surgeon noticed uo (ureteral orifice) off trigone laterally.Patient developed right flank pain after 45 months.Left kidney ultra sonograpphy showed gr 4 hun and mag3: 43->13% df.Patient was treated with open ureteral re-implantation with extravesical dissection.
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
The device is not available to return for evaluation, and the lot number was not provided; therefore a dhr review could not be performed.Based on the current information the root cause of the event could not be conclusively determined.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
DEFLUX INJECTABLE GEL
Type of Device
AGENT,BULKING,INJECTABLE FOR GASTRO-UROLOGY USE
Manufacturer (Section D)
SALIX PHARMACEUTICALS, INC.
raleigh NC
Manufacturer (Section G)
Q-MED
seminariegatan 21
uppsala 75228
SW   75228
Manufacturer Contact
faranak gomarooni
50 technology drive west
irvine, CA 92618
9493985708
MDR Report Key6067906
MDR Text Key58813570
Report Number0001313525-2016-00501
Device Sequence Number1
Product Code LNM
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P000029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type literature
Reporter Occupation Physicist
Type of Report Initial,Followup,Followup
Report Date 10/04/2016
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Physician
Device Model NumberDEFLUX
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 10/04/2016
Initial Date FDA Received10/31/2016
Supplement Dates Manufacturer ReceivedNot provided
10/04/2016
Supplement Dates FDA Received02/14/2017
10/27/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age7 YR
-
-